PDF herunterladen
The Journal of Hip Surgery 2019; 03(01): 034-040
DOI: 10.1055/s-0039-1678743
Special Section Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Metastatic Disease, Myeloma, and Lymphoma Affecting the Hip

Arianna L. Gianakos
1   Department of Orthopaedic Surgery, Jersey City Medical Center - RWJBarnabas Health, Jersey City, New Jersey
,
Jay N. Patel
2   Division of Orthopaedic Oncology, Department of Orthopaedic Surgery, Morristown Medical Center – Atlantic Health System, Morristown, New Jersey
,
Justin M. Miller
1   Department of Orthopaedic Surgery, Jersey City Medical Center - RWJBarnabas Health, Jersey City, New Jersey
,
Laura Sonnylal
3   Department of Orthopaedic Surgery, Hackensack University Medical Center, Hackensack, New Jersey
,
James C. Wittig
2   Division of Orthopaedic Oncology, Department of Orthopaedic Surgery, Morristown Medical Center – Atlantic Health System, Morristown, New Jersey
› Institutsangaben
Weitere Informationen

Publikationsverlauf

31. August 2018

06. November 2018

Publikationsdatum:
15. Februar 2019 (online)

   Lizenzen und Reprints

Abstract

The three most common causes for bony lesions in patients over 40 years of age are metastatic disease, multiple myeloma, and lymphoma. Oftentimes, these conditions have a predilection for the hip region. The authors present the incidence, characteristics, and treatment of metastatic disease, multiple myeloma, and lymphoma affecting the hip joint to help clinicians accurately diagnose and manage these conditions. They also present the senior author's technique of cemented long stem hemiarthroplasty for treating these conditions when they affect the proximal femur.

Keywords

orthopaedic oncology - malignant - metastatic disease - multiple myeloma - lymphoma
 

  • References

  • 1 Decaux O, Lodé L, Minvielle S, Avet-Loiseau H. [Genetic abnormalities in multiple myeloma: role in oncogenesis and impact on survival]. Rev Med Interne 2007; 28 (10) 677-681
    CrossrefPubMedGoogle Scholar
  • 2 Avet-Loiseau H. Role of genetics in prognostication in myeloma. Best Pract Res Clin Haematol 2007; 20 (04) 625-635
    CrossrefPubMedGoogle Scholar
  • 3 Sergentanis TN, Zagouri F, Tsilimidos G. , et al. Risk factors for multiple myeloma: a systematic review of meta-analyses. Clin Lymphoma Myeloma Leuk 2015; 15 (10) 563-77.e1 , 3
    CrossrefPubMedGoogle Scholar
  • 4 Rajkumar SV, Kyle RA. Treatment of multiple myeloma and related disorders. Cambridge; New York: Cambridge University Press; 2009
    Google Scholar
  • 5 Melton III LJ, Kyle RA, Achenbach SJ, Oberg AL, Rajkumar SV. Fracture risk with multiple myeloma: a population-based study. J Bone Miner Res 2005; 20 (03) 487-493
    PubMedGoogle Scholar
  • 6 Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004; 350 (16) 1655-1664
    CrossrefPubMedGoogle Scholar
  • 7 Kyle RA. Multiple myeloma: review of 869 cases. Mayo Clin Proc 1975; 50 (01) 29-40
    PubMedGoogle Scholar
  • 8 Gleeson TG, Moriarty J, Shortt CP. , et al. Accuracy of whole-body low-dose multidetector CT (WBLDCT) versus skeletal survey in the detection of myelomatous lesions, and correlation of disease distribution with whole-body MRI (WBMRI). Skeletal Radiol 2009; 38 (03) 225-236
    CrossrefPubMedGoogle Scholar
  • 9 Princewill K, Kyere S, Awan O, Mulligan M. Multiple myeloma lesion detection with whole body CT versus radiographic skeletal survey. Cancer Invest 2013; 31 (03) 206-211
    CrossrefPubMedGoogle Scholar
  • 10 Wolf MB, Murray F, Kilk K. , et al. Sensitivity of whole-body CT and MRI versus projection radiography in the detection of osteolyses in patients with monoclonal plasma cell disease. Eur J Radiol 2014; 83 (07) 1222-1230
    CrossrefPubMedGoogle Scholar
  • 11 Moulopoulos LA, Dimopoulos MA, Weber D, Fuller L, Libshitz HI, Alexanian R. Magnetic resonance imaging in the staging of solitary plasmacytoma of bone. J Clin Oncol 1993; 11 (07) 1311-1315
    CrossrefPubMedGoogle Scholar
  • 12 Baur A, Stäbler A, Brüning R. , et al. Diffusion-weighted MR imaging of bone marrow: differentiation of benign versus pathologic compression fractures. Radiology 1998; 207 (02) 349-356
    CrossrefPubMedGoogle Scholar
  • 13 Zamagni E, Nanni C, Patriarca F. , et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica 2007; 92 (01) 50-55
    CrossrefPubMedGoogle Scholar
  • 14 Regelink JC, Minnema MC, Terpos E. , et al. Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review. Br J Haematol 2013; 162 (01) 50-61
    CrossrefPubMedGoogle Scholar
  • 15 Terpos E, Morgan G, Dimopoulos MA. , et al. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol 2013; 31 (18) 2347-2357
    CrossrefPubMedGoogle Scholar
  • 16 Palumbo A, Sezer O, Kyle R. , et al; IMWG. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia 2009; 23 (10) 1716-1730
    CrossrefPubMedGoogle Scholar
  • 17 Mhaskar R, Kumar A, Miladinovic B, Djulbegovic B. Bisphosphonates in multiple myeloma: an updated network meta-analysis. Cochrane Database Syst Rev 2017; 12: CD003188
    PubMedGoogle Scholar
  • 18 Raje N, Terpos E, Willenbacher W. , et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol 2018; 19 (03) 370-381
    CrossrefPubMedGoogle Scholar
  • 19 Scharschmidt TJ, Lindsey JD, Becker PS, Conrad EU. Multiple myeloma: diagnosis and orthopaedic implications. J Am Acad Orthop Surg 2011; 19 (07) 410-419
    CrossrefPubMedGoogle Scholar
  • 20 Steinbach M, Richards T, Faiman B. Strategies for selecting the optimal treatment in newly diagnosed multiple myeloma patients. Semin Oncol Nurs 2017; 33 (03) 254-264
    CrossrefPubMedGoogle Scholar
  • 21 Mateos MV, San Miguel JF. Management of multiple myeloma in the newly diagnosed patient. Hematology (Am Soc Hematol Educ Program) 2017; 2017 (01) 498-507
    CrossrefPubMedGoogle Scholar
  • 22 Alvi HM, Damron TA. Prophylactic stabilization for bone metastases, myeloma, or lymphoma: do we need to protect the entire bone?. Clin Orthop Relat Res 2013; 471 (03) 706-714
    CrossrefPubMedGoogle Scholar
  • 23 Utzschneider S, Schmidt H, Weber P, Schmidt GP, Jansson V, Dürr HR. Surgical therapy of skeletal complications in multiple myeloma. Int Orthop 2011; 35 (08) 1209-1213
    CrossrefPubMedGoogle Scholar
  • 24 Harrington KD. New trends in the management of lower extremity metastases. Clin Orthop Relat Res 1982; (169) 53-61
    PubMedGoogle Scholar
  • 25 Levy RN, Sherry HS, Siffert RS. Surgical management of metastatic disease of bone at the hip. Clin Orthop Relat Res 1982; (169) 62-69
    PubMedGoogle Scholar
  • 26 D'Antonio JA, Capello WN, Borden LS. , et al. Classification and management of acetabular abnormalities in total hip arthroplasty. Clin Orthop Relat Res 1989; (243) 126-137
    PubMedGoogle Scholar
  • 27 Angtuaco EJ, Fassas AB, Walker R, Sethi R, Barlogie B. Multiple myeloma: clinical review and diagnostic imaging. Radiology 2004; 231 (01) 11-23
    CrossrefPubMedGoogle Scholar
  • 28 Ludwig H, Durie BG, Bolejack V. , et al. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. Blood 2008; 111 (08) 4039-4047
    CrossrefPubMedGoogle Scholar
  • 29 Parikh SN, Kreder HJ. Pelvic reconstruction for massive acetabular insufficiency. Clin Orthop Relat Res 2005; (434) 217-221
    PubMedGoogle Scholar
  • 30 Freeman C, Berg JW, Cutler SJ. Occurrence and prognosis of extranodal lymphomas. Cancer 1972; 29 (01) 252-260
    CrossrefPubMedGoogle Scholar
  • 31 Limb D, Dreghorn C, Murphy JK, Mannion R. Primary lymphoma of bone. Int Orthop 1994; 18 (03) 180-183
    PubMedGoogle Scholar
  • 32 Newcomer LN, Silverstein MB, Cadman EC, Farber LR, Bertino JR, Prosnitz LR. Bone involvement in Hodgkin's disease. Cancer 1982; 49 (02) 338-342
    CrossrefPubMedGoogle Scholar
  • 33 Binesh F, Mirjalili MR, Akhavan A, Navabii H. Primary bony Hodgkin's lymphoma. BMJ Case Rep 2012; 2012: 201
    PubMedGoogle Scholar
  • 34 Tang F, Min L, Ye Y. , et al. Classic Hodgkin lymphoma in pelvis: a case report highlights diagnosis and treatment challenges. Medicine (Baltimore) 2017; 96 (39) e8196
    PubMedGoogle Scholar
  • 35 Fletcher CDM. , World Health Organization. International Agency for Research on Cancer. WHO Classification of Tumours of Soft Tissue and Bone. 4th ed. Lyon: IARC Press; 2013
    Google Scholar
  • 36 Auerbach A, Aguilera NS. Epstein-Barr virus (EBV)-associated lymphoid lesions of the head and neck. Semin Diagn Pathol 2015; 32 (01) 12-22
    CrossrefPubMedGoogle Scholar
  • 37 Vockerodt M, Yap LF, Shannon-Lowe C. , et al. The Epstein-Barr virus and the pathogenesis of lymphoma. J Pathol 2015; 235 (02) 312-322
    CrossrefPubMedGoogle Scholar
  • 38 Linke-Serinsöz E, Fend F, Quintanilla-Martinez L. Human immunodeficiency virus (HIV) and Epstein-Barr virus (EBV) related lymphomas, pathology view point. Semin Diagn Pathol 2017; 34 (04) 352-363
    CrossrefPubMedGoogle Scholar
  • 39 Paydas S. Hepatitis C virus and lymphoma. Crit Rev Oncol Hematol 2015; 93 (03) 246-256
    CrossrefPubMedGoogle Scholar
  • 40 Schinasi L, Leon ME. Non-Hodgkin lymphoma and occupational exposure to agricultural pesticide chemical groups and active ingredients: a systematic review and meta-analysis. Int J Environ Res Public Health 2014; 11 (04) 4449-4527
    CrossrefPubMedGoogle Scholar
  • 41 Czarnota J, Gennings C, Colt JS. , et al. Analysis of environmental chemical mixtures and non-Hodgkin lymphoma risk in the NCI-SEER NHL study. Environ Health Perspect 2015; 123 (10) 965-970
    CrossrefPubMedGoogle Scholar
  • 42 Lauby-Secretan B, Loomis D, Grosse Y. , et al; WHO International Agency for Research on Cancer. Carcinogenicity of polychlorinated biphenyls and polybrominated biphenyls. Lancet Oncol 2013; 14 (04) 287-288
    CrossrefPubMedGoogle Scholar
  • 43 Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971; 31 (11) 1860-1861
    PubMedGoogle Scholar
  • 44 Lister TA, Crowther D, Sutcliffe SB. , et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7 (11) 1630-1636
    CrossrefPubMedGoogle Scholar
  • 45 Demircay E, Hornicek Jr FJ, Mankin HJ, Degroot III H. Malignant lymphoma of bone: a review of 119 patients. Clin Orthop Relat Res 2013; 471 (08) 2684-2690
    CrossrefPubMedGoogle Scholar
  • 46 Beal K, Allen L, Yahalom J. Primary bone lymphoma: treatment results and prognostic factors with long-term follow-up of 82 patients. Cancer 2006; 106 (12) 2652-2656
    CrossrefPubMedGoogle Scholar
  • 47 Habermann ET, Sachs R, Stern RE, Hirsh DM, Anderson Jr WJ. The pathology and treatment of metastatic disease of the femur. Clin Orthop Relat Res 1982; (169) 70-82
    PubMedGoogle Scholar
  • 48 Sim FH. Metastatic bone disease of the pelvis and femur. Instr Course Lect 1992; 41: 317-327
    PubMedGoogle Scholar
  • 49 Gainor BJ, Buchert P. Fracture healing in metastatic bone disease. Clin Orthop Relat Res 1983; (178) 297-302
    PubMedGoogle Scholar
  • 50 Mirels H. Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathologic fractures. Clin Orthop Relat Res 1989; (249) 256-264
    PubMedGoogle Scholar
  • 51 Hultborn R, Gundersen S, Ryden S. , et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomized, double-blind placebo-controlled multicenter study. Anticancer Res 1999; 19 (4C): 3383-3392
    PubMedGoogle Scholar
  • 52 O'Carrigan B, Wong MH, Willson ML, Stockler MR, Pavlakis N, Goodwin A. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev 2017; 10: CD003474
    PubMedGoogle Scholar
  • 53 Gnant M, Mlineritsch B, Schippinger W. , et al; ABCSG-12 Trial Investigators. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009; 360 (07) 679-691
    CrossrefPubMedGoogle Scholar
  • 54 Fizazi K, Lipton A, Mariette X. , et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009; 27 (10) 1564-1571
    CrossrefPubMedGoogle Scholar
  • 55 Stopeck AT, Lipton A, Body JJ. , et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010; 28 (35) 5132-5139
    CrossrefPubMedGoogle Scholar
  • 56 Sun S, Lang EV. Bone metastases from renal cell carcinoma: preoperative embolization. J Vasc Interv Radiol 1998; 9 (02) 263-269
    CrossrefPubMedGoogle Scholar
  • 57 Chatziioannou AN, Johnson ME, Pneumaticos SG, Lawrence DD, Carrasco CH. Preoperative embolization of bone metastases from renal cell carcinoma. Eur Radiol 2000; 10 (04) 593-596
    CrossrefPubMedGoogle Scholar
  • 58 Coleman RE. Skeletal complications of malignancy. Cancer 1997; 80 (8, Suppl): 1588-1594
    CrossrefPubMedGoogle Scholar
  • 59 Menendez L. OKU Musculoskeletal Tumors (Orthopaedic Knowledge Update). 1st ed. Rosemont, IL: American Academy of Orthopaedic Surgeons; 2001
    PubMed
  • 60 Sarahrudi K, Greitbauer M, Platzer P, Hausmann JT, Heinz T, Vécsei V. Surgical treatment of metastatic fractures of the femur: a retrospective analysis of 142 patients. J Trauma 2009; 66 (04) 1158-1163
    CrossrefPubMedGoogle Scholar
  • 61 Peterson JR, Decilveo AP, O'Connor IT, Golub I, Wittig JC. What are the functional results and complications with long stem hemiarthroplasty in patients with metastases to the proximal femur?. Clin Orthop Relat Res 2017; 475 (03) 745-756
    CrossrefPubMedGoogle Scholar
  • 62 Steensma M, Boland PJ, Morris CD, Athanasian E, Healey JH. Endoprosthetic treatment is more durable for pathologic proximal femur fractures. Clin Orthop Relat Res 2012; 470 (03) 920-926
    CrossrefPubMedGoogle Scholar
  • 63 Janssen SJ, Kortlever JT, Ready JE. , et al. Complications after surgical management of proximal femoral metastasis: a retrospective study of 417 patients. J Am Acad Orthop Surg 2016; 24 (07) 483-494
    CrossrefPubMedGoogle Scholar
  • 64 Harrington KD, Sim FH, Enis JE, Johnston JO, Diok HM, Gristina AG. Methylmethacrylate as an adjunct in internal fixation of pathological fractures. Experience with three hundred and seventy-five cases. J Bone Joint Surg Am 1976; 58 (08) 1047-1055
    CrossrefPubMedGoogle Scholar